Clinical trial
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
NCT01421056 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2011
- Completion date
- November 30, 2012
- Enrollment
- 74 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer's disease